AI driven growth Teiko's rapid product expansion, including AI powered Pocket Immunologist and dashboard upgrades, signals a strong inclination toward scalable, software-enabled solutions that can be upsold to pharmaceutical clients running immune-oncology trials.

Clinical trial focus With a CLIA registered lab and a mission centered on immune measurement for clinical trials, Teiko is a compelling partner for sponsors conducting immunotherapy studies seeking high-dimensional cytometry insights.

Strategic partnerships Recent collaboration with Massachusetts General Hospital on CD38 related T cell signatures indicates open doors for co-developed studies and tiered service offerings to larger research networks.

Data analytics edge Investment in dashboards, automatic statistics, and data tooling suggests opportunities to sell expanded analytics packages, automated reporting, and integration with existing sponsor data ecosystems.

Growth potential Revenue range and $12M funding, combined with a lean team, point to high growth potential through expanding capacity, regional outreach, and enterprise sales to mid-to-large pharma companies seeking immune profiling services.